Systems biology orders strategy to avoid cross-drug resistance in cancer

A Harvard and Mitra Biotech team use systems biology modeling to uncover a three-drug regimen that bypasses breast cancer resistance

A Harvard and Mitra Biotech team used systems biology to identify a temporal treatment regimen that uses a glucose metabolism inhibitor to overcome cross-drug resistance in breast cancer.

Chemotherapies are often administered in combination regimens to make it harder for tumors to resist treatment. But aggressive

Read the full 457 word article

User Sign In